Skip to main content
SpringerLink
Log in

Genetic diversity

Accounting for diversity in the design of CRISPR-based therapeutic genome editing

  • News & Views
  • Published:

From Nature Genetics

View current issue Submit your manuscript

CRISPR cell and gene therapy have been designed largely with respect to a single reference human genome. A new study reveals how human genetic diversity could lead to off-target effects and presents a new tool to identify these risks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Assaying human genetic diversity can advance the design of human therapeutics involving genome editing.

References

  1. Graham, F. Nature https://doi.org/10.1038/d41586-020-01928-y (2020).

  2. Science News Staff. Science https://doi.org/10.1126/science.adf7363 (2022).

  3. Cancellieri, S. et al. Nat. Genet. https://doi.org/10.1038/s41588-022-01257-y (2022).

  4. Sinha, D. et al. Am. J. Hum. Genet. 107, 278–292 (2020).

    Article  CAS  Google Scholar 

  5. Keough, K. C. et al. Genome Biol. 20, 167 (2019).

    Article  Google Scholar 

  6. Saha, K. et al. Nature 592, 195–204 (2021).

    Article  CAS  Google Scholar 

  7. Misek, S. A. et al. Preprint at bioRxiv https://doi.org/10.1101/2022.11.18.517155 (2022).

  8. Lessard, S. et al. Proc. Natl Acad. Sci. USA 114, E11257–E11266 (2017).

    Article  CAS  Google Scholar 

  9. Scott, D. A. & Zhang, F. Nat. Med. 23, 1095–1101 (2017).

    Article  CAS  Google Scholar 

  10. Leibowitz, M. L. et al. Nat. Genet. 53, 895–905 (2021).

    Article  CAS  Google Scholar 

  11. Maeder, M. L. et al. Nat. Med. 25, 229–233 (2019).

    Article  CAS  Google Scholar 

  12. Musunuru, K. et al. Nature 593, 429–434 (2021).

    Article  CAS  Google Scholar 

  13. Foy, S. P. et al. Nature https://doi.org/10.1038/s41586-022-05531-1 (2022).

  14. Center for Biologics Evaluation and Research. Human Gene Therapy Products Incorporating Human Genome Editing (U.S. Food and Drug Administration, 2022).

Download references

Acknowledgements

K.S. has received funding from the US National Science Foundation, grant nos. EEC-1648035 and AWD-101645-G3/RJ375-G3, and the US National Institutes for Health, grant nos. R35GM119644, U01EY032333 and UH3NS111688.

Author information

Authors and Affiliations

  1. Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA

    Krishanu Saha

  2. McPherson Eye Research Institute, University of Wisconsin-Madison, Madison, WI, USA

    Krishanu Saha

  3. Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, USA

    Krishanu Saha

  4. Department of Medical History & Bioethics, University of Wisconsin-Madison, Madison, WI, USA

    Krishanu Saha

Authors
  1. Krishanu Saha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Krishanu Saha.

Ethics declarations

Competing interests

K.S. receives sponsored research support from Spotlight Therapeutics and Synthego and is an advisor to Notch Therapeutics and Andson Biotech.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saha, K. Accounting for diversity in the design of CRISPR-based therapeutic genome editing. Nat Genet 55, 6–7 (2023). https://doi.org/10.1038/s41588-022-01272-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41588-022-01272-z

  • Springer Nature America, Inc.

Search

Navigation